Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Douglas Taylor

Podiatrist, Primary Podiatric Medicine San Leandro, CA Doctor of Podiatric Medicine

NPI 1518915693 CMS profile 114594

13847E 14Th St 110A, Suite 30, San Leandro, CA 94578

Open in the dashboard

General payments

$3,018

36 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Douglas Taylor of San Leandro, CA is reported in the CMS Open Payments database as having received $3,018 across 36 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Podiatrist, Primary Podiatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $388 3
2024 General $619 8
2023 General $459 7
2022 General $576 6
2021 General $177 3
2020 General $57 2
2019 General $743 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Douglas Taylor
  • Podiatrist, Primary Podiatric Medicine median
  • Middle half of Podiatrist, Primary Podiatric Medicine
  • National median

In program year 2025, general payments to Douglas Taylor were reported at $388. Among 368 Podiatrist, Primary Podiatric Medicine profiles paid that year, the median was $232 and the middle half received between $88 and $586.

Show as a table
Year Douglas Taylor Podiatrist, Primary Podiatric Medicine median Middle half National median
2019 $743 $166 $51–$513 $163
2020 $57 $108 $33–$249 $114
2021 $177 $147 $52–$377 $132
2022 $576 $188 $66–$551 $149
2023 $459 $195 $70–$509 $160
2024 $619 $209 $59–$508 $164
2025 $388 $232 $88–$586 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Smith+Nephew, Inc. $884 13 payments
  2. Bioventus LLC $586 4 payments
  3. Organogenesis Inc. $415 5 payments
  4. Orthofix Medical, Inc. $198 2 payments
  5. Zimmer Biomet Holdings, Inc. $179 2 payments
  6. Kerecis Limited $179 1 payment
  7. Treace Medical Concepts, Inc. $164 2 payments
  8. Musculoskeletal Transplant Foundation Inc. $140 2 payments
  9. Bone Support Inc. $111 1 payment
  10. Crossroads Extremity Systems, LLC $92 1 payment
  11. Other $68 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,893 35 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $125 1 payment
Products named General payments · program years 2019–2025
  1. COLLAGENASE SANTYL $414 9 payments
  2. EXOGEN ULTRASOUND BONE HEALING SYSTEM $305 2 payments
  3. Physio-Stim $283 3 payments
  4. Apligraf $234 2 payments
  5. Dermagraft $234 2 payments
  6. Puraply/Affinity/NuTech $234 2 payments
  7. Kerecis Omega3 SurgiClose $179 1 payment
  8. Kerecis Omega3 Marigen Wound Care $179 1 payment
  9. Kerecis Omega3 Marigen Wound Care $179 1 payment
  10. Kerecis Omega3 Marigen Wound Care $179 1 payment
  11. Other $2,527 30 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

257

Median for Podiatry: 160

Drug cost

$10,473

Median for Podiatry: $2,368

Branded share of claims

17.5%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tavaborole Generic 30 $6,648
Ketoconazole Generic 60 $1,457
Ciclopirox Ciclopirox Olamine Brand 34 $1,080
Allopurinol Generic 30 $290
Triamcinolone Acetonide Generic 13 $275
Mupirocin Generic 27 $271
Cephalexin Generic 20 $143
Meloxicam Generic 21 $141
Fluconazole Generic 11 $108
Ssd Silver Sulfadiazine Brand 11 $59

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$172,472

Of which drugs: $202

Medicare patients

258

Average age 79

Services billed

1,772

150 women, 108 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Chronic kidney disease 31%
Diabetes 30%
Ischemic heart disease 23%
Osteoporosis 21%
Atrial fibrillation 20%
Depression 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 17 34 $184
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 26 122 $10

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

36 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Primary Podiatric Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record